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Abstract: In the past few years the classical concept of the renin–angiotensin system (RAS) 
has experienced substantial conceptual changes. The identiﬁ  cation of the renin/prorenin recep-
tor, the angiotensin-converting enzyme homologue ACE2 as an angiotensin peptide processing 
enzyme, Mas as a receptor for Ang-(1-7) and the possibility of signaling through ACE, have 
contributed to switch our understanding of the RAS from the classical limited-proteolysis linear 
cascade to a cascade with multiple mediators, multiple receptors, and multi-functional enzymes. 
In this review we will focus on the recent ﬁ  ndings related to RAS and, in particular, on its role 
in diabetes by discussing possible interactions between RAS mediators, endothelium function, 
and insulin signaling transduction pathways as well as the putative role of ACE2-Ang-(1-7)-
Mas axis in disease pathogenesis.
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Introduction
In a classical view, the renin–angiotensin system (RAS) is considered an endocrine 
system whose active metabolite, the angiotensin II (Ang II), is produced by enzymatic 
sequential cleavage from the angiotensinogen substratum of hepatic origin (Weber 
et al 2001; Zaman et al 2002). In the bloodstream, the renin, a highly speciﬁ  c protease, 
converts the circulating angiotensinogen into the decapeptide Ang I, which, in turn is 
converted to Ang II by the angiotensin-converting enzyme (ACE) action (Weber et al 
2001; Zaman et al 2002). This enzyme also inactivates bradykinin (BK) and is highly 
found in the endothelial cells membranes of the pulmonary circulation (Weber et al 
2001; Zaman et al 2002; Carey and Siragy 2003a).
In the past few years the classical concept of the RAS has experienced substantial 
conceptual changes. Although this system is known for decades, recent discoveries in 
cellular and molecular biology, as well as cardiovascular and renal physiology, have 
introduced larger understanding about its function in physiological situations and in 
several diseases (Carey and Siragy 2003a; Chappell et al 2004; Simões e Silva et al 
2006a; Santos and Ferreira 2007; Chappell 2007).
One of the most relevant conceptual changes in our understanding of the RAS was 
the discovery of local or tissue RAS (Miyazaki and Takai 2006; Paul et al 2006). A 
local system is characterized by the presence of RAS components, such as angioten-
sinogen, processing enzymes, angiotensins, and speciﬁ  c receptors at tissue level. In 
the 70’s, Ganten and colleagues (1971) demonstrated, for the ﬁ  rst time, that all RAS’s 
components could be produced locally in several organs and tissues. The local RAS 
has been found in the heart, blood vessels, kidney, adrenal gland, pancreas, central 
nervous system, reproductive system, lymphatic and adipose tissue (Nielsen et al 2000; 
Sernia 2001; Lavoie and Sigmund 2003; Spät and Hunyady 2004). The local systems 
appear to be regulated independently of the circulatory RAS but can also interact with Vascular Health and Risk Management 2008:4(4) 788
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the latter. In this way, local RAS’s effects could occur in 
the cell that produces the peptides (intracrine and autocrine 
functions), in adjacent cells (paracrine function) or through 
the bloodstream to a speciﬁ  c organ or tissue (endocrine 
function) (Miyazaki and Takai 2006; Paul et al 2006). The 
main importance of tissue RAS is linked to local regulatory 
mechanisms that contribute to a great number of homeostatic 
pathways, including cellular growth, extracellular matrix 
formation, vascular proliferation, endothelium function and 
apoptosis (Miyazaki and Takai 2006; Paul et al 2006).
Other important landmarks for the new concept of RAS 
were the characterization of angiotensin-(1-7) [Ang-(1-7)] as 
a biological active metabolite of RAS (Simões e Silva et al 
2006a; Santos and Ferreira 2007), the Ang IV receptor as 
an insulin-regulated aminopeptidase (IRAP) (Albiston et al 
2001), the renin/prorenin receptor (Nguyen et al 2002), the 
ACE homologue ACE2 as an angiotensin peptide processing 
enzyme (Donoghue et al 2000; Tipnis et al 2000), Mas as a 
receptor for Ang-(1-7) (Santos et al 2003), and the possibil-
ity of signaling through ACE (Kohlstedt et al 2004). These 
discoveries have contributed to switch our understanding of 
the RAS from the classical limited-proteolysis linear cascade 
to a cascade with multiple mediators, multiple receptors, and 
multi-functional enzymes (Simões e Silva et al 2006a; Santos 
and Ferreira 2007; Chappell 2007) (Figure 1).
In regard to Ang-(1-7), the identiﬁ  cation of ACE2 and 
Mas as a receptor implicated in its actions contributed to 
decisively establish this heptapeptide as a biologically active 
member of the RAS cascade. Most evidence supports a 
counter-regulatory role for Ang-(1-7) by opposing many Ang 
II-AT1 receptor-mediated actions, especially vasoconstriction 
and proliferation (Simões e Silva et al 2006a; Santos and 
Ferreira 2007; Chappell 2007). Furthermore, Ang-(1-7) has 
been associated to the physiopathology of several diseases 
such as hypertension (Luque et al 1996; Ferrario et al 1998; 
Simões e Silva et al 2004, 2006b, 2006c), pre-eclampsia 
(Merril et al 2002; Brosnihan et al 2004; Shah 2005), hyper-
trophic myocardial disease and congestive heart failure, 
myocardial infarct (Zisman et al 2003; Santos and Ferreira 
2005), chronic renal diseases (Simões e Silva et al 2006b), 
hepatic cirrhosis (Paizis et al 2005; Pereira et al 2007; Herath 
et al 2007; Warner et al 2007), diabetic nephropathy (Carey 
and Siragy 2003b; Tikelis et al 2003; Kalantrina and Okusa 
2006), and gestational diabetes (Nogueira et al 2007).
This review will summarize the current aspects of RAS, 
its role in diabetes, and its well-known and putative inter-
actions with endothelium function and insulin signaling. 
Moreover, the importance of the RAS to diabetes prevention 
and its involvement on cardiovascular and renal events in 
diabetic patients will be discussed.
New aspects of the RAS 
components
Angiotensinogen
Angiotensinogen (AGT) is a glycoprotein of 452 aminoacids 
produced in the liver as well as in other tissues (including the 
heart, vessels, kidneys, and adipose tissue), which circulates 
as an inactive biological peptide. Through renin action, it is 
converted into Ang I, the precursor peptide in classical RAS 
cascade (Weber et al 2001).
The M235T polymorphism of the AGT gene is known 
to be associated with circulating and tissue AGT (Bloem 
et al 1995; Winkelmann et al 1999; Gumprecht et al 2000). 
However, the ﬁ  nding of genetic linkage between the AGT 
gene and hypertension in many studies and the presence 
of increased levels of plasma AGT in subjects with higher 
parental and personal blood pressure only support a role for 
increased synthesis of angiotensinogen in hypertension but do 
not explain how this translates into elevated blood pressure 
(Naber and Siffert 2004). One hypothesis is that the genetic 
increase in RAS activity due to the T235 allele of AGT may 
lead to greater formation of Ang II in cardiac, vascular, and 
renal tissues, predisposing to cardiovascular and renal dam-
age (Winkelmann et al 1999; Gumprecht et al 2000).
Renin
Renin is an aspartyl protease enzyme produced by the jux-
taglomerular apparatus of the kidney. This enzyme acts on 
Figure 1 Novel components of the renin–angiotensin system and its interactions.
Abbreviations: Ang, angiotensin, AT1, AT2, angiotensinergic receptors types 1 and 2; 
NO, nitric oxide; ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting 
enzyme 2.
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AGT and forms the decapeptide Ang I. Renin is considered 
a key enzyme of the RAS due to the rate-limiting nature of 
its hydrolytic activity on the precursor AGT (Weber et al 
2001; Zaman et al 2002).
In recent years, this view has acquired new and important 
features after the discovery of the renin/prorenin receptor 
by Nguyen and colleagues (2002). Thus, according to our 
new understanding of the role of renin within the RAS, it 
serves as an Ang II-generating enzyme through the limited-
proteolysis process started by its action on AGT and it can 
act as an agonist of the RAS inducing signaling through its 
receptor. In addition, binding of renin to its receptor appears 
to increase its catalytic efﬁ  ciency on its substrate. We are 
still searching for the biological and physiopathological 
implications of these actions, but there are suggestions that 
it may be implicated in target-organ lesion, especially in the 
kidney (Staessen et al 2006).
Angiotensin-converting enzyme
The key role of angiotensin-converting enzyme (ACE) within 
the RAS is well established since the pioneering work of 
Skeggs and colleagues (1956), which showed that ACE is 
the main Ang II-generating enzyme. About 40 years later, 
the action of ACE in the catabolism of Ang-(1-7) was clearly 
established (Deddish et al 1998). As shown in Figure 1, by 
forming the potent vasoconstrictor Ang II and inactivating the 
vasodilator Ang-(1-7), ACE plays a central role as a pressor 
enzyme. Another action outside the RAS, the inactivation of 
the vasodilator BK, further strengthens the role of ACE as a 
pro-hypertensive enzyme.
However, the role of ACE is not restricted to its hydro-
lytic activity. Fleming and colleagues (Kohlstedt et al 2004) 
have identiﬁ  ed a new action of ACE: the out-in signaling. 
According to this novel view, upon binding by bradykinin 
(BK) and ACE inhibitors (ACEi), ACE is phosphorylated at 
the amino acid Ser1270 and triggers a signal cascade, which 
was able to increase ACE and COX-2 synthesis. In addition, 
the signaling through ACE was described in adipocytes and 
pre-adipocytes (Kohlstedt et al 2004).
Angiotensin-converting enzyme 2
In 2000, two independent groups (Donoghue et al 2000; 
Tipnis et al 2000) identiﬁ  ed a new enzyme homologue of 
ACE, which they called angiotensin-converting enzyme 2 
(ACE2) (Donoghue et al 2000) and captopril insensitive 
carboxypeptidase (Tipnis et al 2000). This enzyme shows a 
homology of about 42% with ACE, but different biochemi-
cal activities, being highly speciﬁ  c for angiotensin cleavage. 
For example, in contrast to classical ACE, ACE2 does not 
metabolize BK.
In the original work of Donoghue and colleagues (2000), 
ACE2 was described as having as a primary activity the 
hydrolysis of Ang I, generating Ang-(1-9), serving as an indi-
rect pathway to generate Ang II. However, this interpretation 
was challenged by the demonstration that Ang II was the pref-
erable substrate for ACE2 (Tipnis et al 2000; Vickers et al 
2002). Indeed, the catalytic efﬁ  ciency of ACE2 against Ang 
II is 400-fold higher than for Ang I and leads to Ang-(1-7) 
formation (Rice et al 2004). It is also functionally remarkable 
that ACE2 is the main enzyme for Ang-(1-7) generation in 
many tissues (Rice et al 2004; Ferrario et al 2005).
Taking into account the enzymatic properties of the 
two ACEs and of the two main RAS mediators, Ang 
II and Ang-(1-7), we can make out a new vision of the 
RAS. In this novel concept, the RAS can be seen as a dual 
function system in which the vasoconstrictor/proliferative 
or vasodilator/antiproliferative actions are primarily driven 
by the ACE/ACE2 balance (Simões e Silva et al 2006a; 
Santos and Ferreira 2007; Chappell 2007; Warner et al 
2007). According to this concept, an elevated ACE activity 
concomitant with a reduced ACE2 activity will lead to 
increased Ang II generation and increased catabolism of 
Ang-(1-7)-favoring vasoconstriction, while the opposite 
proﬁ  le (elevated ACE2 activity with reduced ACE activity) 
will decrease Ang II levels by converting it into Ang-(1-7), 
which, in turn, promotes vasodilation (Simões e Silva et al 
2006a; Santos and Ferreira 2007; Chappell 2007; Warner 
et al 2007).
Angiotensin II
Ang II was isolated in 1940 by Braun-Menendez and col-
leagues (1940) and Page and Helmer (1940) and was ﬁ  rstly 
characterized as a potent vasoconstrictor that increases 
peripheral vascular resistance and consequently elevates 
arterial pressure. In situations of extracellular ﬂ  uid volume 
contraction, Ang II reduces renal sodium excretion via altera-
tions in renal hemodynamics, direct enhancement of proximal 
tubule sodium bicarbonate reabsorption, and aldosterone-
mediated increases in late distal tubule and cortical collecting 
duct reabsorption (Hall 1991; Ichikawa and Harris 1991; 
Hall et al 1999; Brewster and Perazella 2004). Ang II also 
increases thirst, salt appetite, and intestinal sodium absorp-
tion, all of which increase the extracellular ﬂ  uid volume. In 
this context, the RAS was initially deﬁ  ned as an endocrine 
system in which circulating Ang II regulates blood pressure 
and electrolyte balance via its actions on vascular tone, Vascular Health and Risk Management 2008:4(4) 790
Ribeiro-Oliveira et al
aldosterone secretion, renal sodium handling, thirst, water 
intake, sympathetic activity, and vasopressin release.
Additional experimental studies as well as clinical tri-
als using ACE inhibitors and Ang II type 1 (AT1) recep-
tor blockers have shown that the actions of this system 
extend far beyond blood pressure control and electrolyte 
balance (Ferrario et al 2004). It has become clear that the 
deleterious actions of RAS on cardiovascular remodeling 
and renal function account for the beneﬁ  cial effects of the 
ACE inhibitors and AT1 receptor blockers in patients with 
hypertension, left ventricular hypertrophy, heart failure, 
and diabetic nephropathy (Ferrario et al 2004). However, 
besides circulating RAS, Ang II as well as other RAS 
mediators can also be locally produced and exert paracrine, 
intracrine, and autocrine effects (Myiazaki and Takai 2006). 
One of the ﬁ  rst evidence for the tissue formation of Ang II 
came from studies on angiotensin metabolism in sheep (Fei 
et al 1980). The octapeptide was subsequently found to be 
produced in numerous tissues, including the adrenal, brain, 
heart, kidney, vasculature, adipose tissue, gonads, pancreas, 
prostate, eye, and placenta (Nielsen et al 2000; Sernia 2001; 
Lavoie and Sigmund 2003; Spät and Hunyady 2004; Navar 
and Nishiyama 2004; Brewster and Perazella 2004). Further 
investigations proposed that in the circulating RAS, renin 
originating from the kidney is a rate-limiting factor for Ang 
II generation in plasma, but in the vascular tissue, ACE and 
other peptidases such as chymase regulate Ang II generation 
(Myiazaki and Takai 2006). Although not all components of 
the classical RAS are synthesized locally in some tissues, 
alternative enzymatic pathways or the presence of the renin 
receptor, which binds to and activates circulating renin and 
prorenin (Nguyen et al 2002), may also permit local Ang II 
formation. In addition, the RAS is also able to exert intracrine 
effects due to the intracellular formation of Ang II (Re 2003; 
Baker et al 2004). However, kinetic studies suggest that 
intracellular Ang II is largely derived from receptor-mediated 
uptake of the extracellular peptide (Danser 2003).
The cellular Ang II receptor was identiﬁ  ed in 1974 as a 
high-afﬁ  nity plasma membrane-binding site that is sensitive 
to guanyl nucleotides (Glossmann et al 1974). Later, distinct 
AT1 and AT2 receptor subtypes were identiﬁ  ed by selective 
ligands (De Gasparo et al 2000) and were subsequently 
characterized as seven transmembrane receptors by molecular 
cloning (Murphy et al 1991; Sasaki et al 1991; Kambayashi 
et al 1993; Mukoyama et al 1993). Thus, Ang II mediates 
effects via complex intracellular signaling pathways that 
are stimulated following binding of the peptide to its cell-
surface receptors, AT1 and AT2 (Murphy et al 1991; Touyz 
and Schiffrin 2000). In humans, AT1 receptor is widely 
expressed in blood vessels, heart, kidney, adrenal glands, and 
liver, whereas AT2 receptor is present mainly in fetal tissue, 
decreasing rapidly after birth, with relatively low amounts 
normally expressed in adult tissue. The G protein-coupled 
AT1 receptor mediates the known physiological and patho-
logical actions of Ang II and undergoes rapid desensitization 
and internalization after agonist stimulation. In contrast, the 
AT2 receptor does not exhibit the latter features and acts 
mainly through Gi and tyrosine phosphatases to exert pre-
dominantly inhibitory actions on cellular responses mediated 
by the AT1 receptor and growth factor receptors (Nouet and 
Nahmias 2000; Hunyady and Catt 2006). For example, both 
receptors play a role in regulating vascular smooth muscle 
cell (VSMC) function, although they differ in their actions. 
While the AT1 receptor is associated with growth, inﬂ  am-
mation and vasoconstriction, the AT2 receptor is generally 
associated with opposite actions stimulating apoptosis and 
vasodilatation (Touyz and Schiffrin 2000).
Animal models and clinical data have also helped to 
establish that inhibition of Ang II action in nonclassical 
target sites, such as immune cells, explains some of the 
unanticipated therapeutic effects of ACE inhibitors and AT1 
receptor blockers (Ferrario et al 2004). Parallel studies on the 
molecular mechanism of action of Ang II have revealed that 
its main target, the AT1 receptor, is one of the most versatile 
members of the G protein-coupled receptor (GPCR) family 
(Hunyady and Catt 2006). Ang II exerts several cytokine-
like actions via the AT1 receptor and can stimulate multiple 
signaling pathways, activate several growth factor recep-
tors, and promote the formation of reactive oxygen species 
(ROS) and other proinﬂ  ammatory responses (Hunyady and 
Catt 2006).
Angiotensin-(1-7)
Ang-(1-7) was regarded as an inactive component of the 
RAS for many years. However after the demonstration that 
Ang-(1-7) was the main product formed from Ang I through 
an ACE-independent pathway, in dog brain micro-punches 
homogenates (Santos et al 1988) and the demonstration that 
this heptapeptide was equipotent to Ang II to elicit vasopres-
sin release from neurohyphophyseal explants (Schiavone et al 
1988) and to decrease blood pressure upon microinjection 
into the nTS (Campagnole-Santos et al 1989), the importance 
of Ang-(1-7) within the RAS became increasingly evident.
Ang-(1-7) is formed from Ang II by prolylendopep-
tidase, prolyl-carboxipeptidase or ACE2 or directly from 
Ang I through hydrolysis by prolylendopeptidase and Vascular Health and Risk Management 2008:4(4) 791
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endopeptidase 24.11 and it is metabolized by ACE to Ang-
(1-5) (Donoughue et al 2000; Tipnis et al 2000; Chappell et al 
2004; Rice et al 2004). ACE inhibitors elevate plasma Ang-
(1-7) concentrations by both increasing Ang I, the substrate 
for Ang-(1-7), as well as by preventing Ang-(1-7) degrada-
tion (see Figure 1). Ang-(1-7) is present in the circulation 
and in many tissues including heart, blood vessels, kidney 
and liver (Simões e Silva et al 2006a; Santos and Ferreira 
2007; Chappell 2007).
The recent identiﬁ  cation of ACE2 which forms Ang-(1-7) 
from Ang II (Donoughue et al 2000; Tipnis et al 2000), 
and the G-protein coupled receptor Mas as an Ang-(1-7) 
receptor (Santos et al 2003) have provided biochemical and 
molecular evidence for the biological signiﬁ  cance of the 
Ang-(1-7). In addition, the inhibitory effects of Ang-(1-7) on 
Ang II-induced vasoconstriction, and its growth-inhibitory, 
antiarrhythmogenic and antithrombogenic effects imply a 
counter regulatory role for this angiotensin within the RAS 
and suggest that this may be a potential target for develop-
ment of new drugs (Simões e Silva et al 2006a; Santos and 
Ferreira 2007; Chappell 2007).
In this regard, recent studies suggest that, at least in part, 
the beneﬁ  cial effects of ACE inhibitors in heart and kidney 
diseases may be attributed to Ang-(1-7) (Simões e Silva 
et al 2006a; Santos and Ferreira 2007). These ﬁ  ndings are 
in agreement with the hypothesis that the RAS is capable to 
self-regulate its activity through the formation of Ang-(1-7). 
In addition, Kostenis and colleagues (2005) recently demon-
strated that the Ang-(1-7) G-protein coupled receptor Mas 
can hetero-oligomerize with AT1 receptor and by so inhibit 
the actions of Ang II. Indeed, Mas receptor acts in vivo as 
an antagonist of the AT1 receptor (Kostenis et al 2005). We 
currently believe that RAS can act through two opposite 
arms: the major one responsible for the main actions of 
this system is constituted by the ACE-Ang II-AT1 receptor 
axis and the other, a counterregulatory arm, is formed by 
the ACE2-Ang-(1-7)-Mas axis (Simões e Silva et al 2006a; 
Santos and Ferreira 2007).
Angiotensin III
Ang III is generated from the metabolism of Ang II by ami-
nopeptidase A, which cleaves the Asp1-Arg2 bound. Ang III 
is a biologically active peptide of the RAS whose effects are 
essentially similar to those observed for Ang II though less 
potent. Ang III enhances blood pressure, vasopressin release, 
and thirst when it is centrally administrated (Cesari et al 
2002). Ang III infusion increases blood pressure in healthy 
volunteers and hypertensive patients (Suzuki et al 1984) as 
well as augments aldosterone release (Plovsing et al 2003). 
Ang III does not affect renal function in humans (Plovsing 
et al 2003), but it induces natriuresis probably through AT2 
receptors stimulation in AT1 receptor-blocked rats (Padia 
et al 2006). In addition, in cultured renal cells this peptide 
stimulates the expression of many growth factors, proinﬂ  am-
matory mediators, and extracellular matrix proteins (Ruiz-
Ortega et al 2000). Ang III normally binds to AT1 and with 
more afﬁ  nity to AT2 receptors (Padia et al 2007). However, 
it is still not established whether these effects of Ang III are 
due to direct action of this peptide at angiotensins` recep-
tors or they are mediated by smaller peptides formed as a 
consequence of its degradation.
Angiotensin IV
Ang IV was generated by the enzyme aminopeptidase N, 
which removes the amino acid arginine from the N-termi-
nus of Ang III sequence. Alternatively, this angiotensin 
fragment can be also formed directly from Ang II by the 
enzyme D-aminopeptidase. Central administration of Ang IV 
markedly enhances learning and memory in normal rodents 
and reverses memory deﬁ  cits observed in animal models 
of amnesia (Chay et al 2004; Braszko et al 2006). In the 
kidney, Ang IV increases renal cortical blood ﬂ  ow without 
altering systemic blood pressure and decreases Na+ transport 
in isolated renal proximal tubules (Chay et al 2004). On the 
other hand, other studies have shown that this peptide can 
decrease total and regional renal blood ﬂ  ow in rats (Li et al 
2006). It has been reported that Ang IV induces vasodilation 
in preconstricted endothelium-intact but not endothelium-
denuded pulmonary artery through a speciﬁ  c binding site 
that is blocked by divalinal (Chen et al 2000). In addition, 
this peptide increases endothelial NO synthase activity and 
cellular cGMP content in porcine pulmonary arterial endothe-
lial cells (Patel et al 1998). In the heart, Ang IV reduced left 
ventricular pressure-development and ejection capabilities 
but increased the sensitivity of pressure development during 
the systole and speeded relaxation (Slinker et al 1999).
Most Ang IV actions are mediated by a speciﬁ  c binding 
site called AT4 receptor. This receptor is found in many 
organs such as brain, adrenal gland, kidney, lung, and heart 
and it mediates the majority of Ang IV actions (Chay et al 
2004; Albiston et al 2007). However, in some circumstances, 
Ang IV can induce its effects by interacting with AT1 recep-
tor (Li et al 2006). It is important to mention that Ang IV 
is not the only ligand for AT4 receptor, since other peptides 
such as LVV-hemorphin 7 can bind to this receptor (Albsi-
ton et al 2004). The AT4 receptor has been also identiﬁ  ed Vascular Health and Risk Management 2008:4(4) 792
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as the transmembrane enzyme, insulin-regulated membrane 
aminopeptidase (IRAP) (Albiston et al 2001). IRAP is a 
type II integral membrane spanning protein belonging to 
the M1 family of aminopeptidases and is predominantly 
found in GLUT4 vesicles in insulin-responsive cells. Three 
hypotheses for the memory-potentiating effects of the AT4 
receptor/IRAP ligands, Ang IV and LVV-hemorphin 7, are 
proposed: acting as potent inhibitors of IRAP, they may 
prolong the action of endogenous promnestic peptides; they 
may modulate glucose uptake by modulating trafﬁ  cking of 
GLUT4; IRAP may act as a receptor, transducing the signal 
initiated by ligand binding to its C-terminal domain to the 
intracellular domain that interacts with several cytoplasmic 
proteins (Chay et al 2004; Albiston et al 2007). However, the 
precise meaning of this ﬁ  nding remains to be elucidated.
Other angiotensin peptides
The physiological relevance of other angiotensin peptides 
is still unclear. Indeed, many studies have been showing the 
presence of these angiotensins in diverse clinical conditions. 
It is possible that the formation of other angiotensins could be 
an alternative mechanism to override different levels of RAS 
blockade, thus interfering with the action of ACE inhibitors 
or AT1 receptor blockers.
Recent reports have attributed some biological actions to 
the smaller fragment of the RAS as the Ang-(3-7). A result of 
the degradation of Ang-(1-7), Ang II, and Ang IV by amino-
peptidase or carboxypeptidase, it is believed that this angio-
tensin plays important role in the brain (Karwowska-Poleska 
et al 1997) and kidney (Handa 1999). Indeed, Ang-(3-7) has 
an afﬁ  nity for AT4 receptors that did differ from Ang IV.
The issue whether Ang-(1-9) itself has direct biological 
effects or whether its supposed actions are elicited by genera-
tion of different metabolites, especially Ang-(1-7), remains 
unsolved. In some pathological conditions, its concentration 
changes signiﬁ  cantly, indicating that it could be involved 
in those diseases (Ocaranza et al 2006). Ang-(1-9) can be 
formed direct from Ang I through catalytic action of ACE2 
and it is metabolized by ACE and NEP to generate Ang-
(1-7) (Rice et al 2004). It has been reported that this peptide 
enhances BK actions, increases NO and arachidonic acid 
release (Jackman et al 2002), and is involved in the regulation 
of platelet function (Mogielnicki et al 2003).
Ang A, also a novel angiotensin peptide, was ﬁ  rstly 
detected in plasma from healthy humans and in end-stage 
renal disease patients (Jankowski et al 2007). Ang A concen-
trations were less than 20% of the Ang II concentrations in 
healthy subjects, but the ratio of Ang A/Ang II has been shown 
as higher in end-stage renal disease patients. In a different way 
from other angiotensin fragments, Des[Asp1]-[Ala1]-Ang II 
is generated by decarboxylation reaction instead of cleavage 
process. Thus, the ﬁ  rst amino acid of the Ang II sequence 
(aspartic acid) is converted into alanine. Conventional enzyme 
immunoassays do not distinguish between Ang II and Ang A. 
Otherwise, these assays quantify the sum of Ang II and Ang 
A. Ang A has similar afﬁ  nity to the AT1 receptor as Ang II, 
but a higher afﬁ  nity to the AT2 receptor. However, its activity 
in in vitro preparations is lower when compared with Ang II. 
Indeed, Ang A is a less potent and only partial agonist at the 
AT1 receptor. On the other hand, due to its high afﬁ  nity to the 
AT2 receptor, it could be an endogenous Ang II regulatory 
peptide (Jankowski et al 2007).
The demonstration of endogenous Ang-(1-12) in the rat 
may foretell renin-independent pathways that lead to the 
formation of biologically active peptides (Nagata et al 2006). 
Indeed, the peptide bond Tyr12-Tyr13 hydrolyzed to produce 
Ang-(1-12) from rat angiotensinogen is structurally distinct 
from the Leu10-Leu11 bond recognized by rat renin to form 
Ang I. Moreover, these bonds are also distinct for human 
angiotensinogen (Nagata et al 2006). Despite the absence of 
a functional effect attributed to Ang-(1-12), the processing 
to this intermediate peptide may comprise another level of 
RAS regulation.
Tables 1 and 2 summarize the results obtained by recent 
basic and clinical research on RAS.
RAS and diabetes
The association of the RAS with the endocrine system is par-
ticularly illustrated by the prominent role of Ang II in diabetes 
and metabolic syndrome. The frequent association of diabetes 
mellitus (DM) with hypertension, retinopathy, nephropathy, 
and cardiovascular disease has implicated the RAS in the initia-
tion and progression of these disorders. This has been demon-
strated by clinical trials in which RAS inhibitors signiﬁ  cantly 
reduced the incidence of vascular complications in DM patients 
(UKPDS 1998; HOPE 2000; Brenner et al 2001; Lewis et al 
2001; Parving et al 2001; Jandeleit-Dahm et al 2005). These 
improvements appear to result from protective actions upon 
skeletal muscle (Muller et al 1997; Frossard et al 2000) and pan-
creatic islets (Lupi et al 2006), and also from enhanced insulin 
sensitivity associated with decreased adipocyte size (Furuhashi 
et al 2004), as well as increased transcapillary glucose transport 
(Muller et al 1997; Frossard et al 2000). Ang II can also cause 
insulin resistance by interfering with the insulin-stimulated 
increase in insulin receptor substrate 1-associated PI3K activity 
(Folli et al 1999) (Figure 2).Vascular Health and Risk Management 2008:4(4) 793
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Table 1 Summary of recent basic research on renin–angiotensin system
Author Results/Interpretations
Abdalla et al 2000 AT1 receptor and the bradykinin (B2) receptor also communicate directly with each other.
Albiston et al 2001 The AT(4) receptor is insulin-regulated aminopeptidase and possibly the AT(4) receptor ligands may exert their 
effects by inhibiting the catalytic activity of insulin-regulated aminopeptidase.
Baker et al 2004 Losartan did not block the growth effects of Ang II, excluding the involvement of extracellular Ang II and the 
plasma membrane AT1 receptor. These data demonstrate a previously unknown growth mechanism of Ang II 
in the heart.
Benter et al 2008 Ang-(1-7) decreased the elevated levels of renal NADPH oxidase (NOX) activity and attenuated the activation 
of NOX-4 gene expression in the diabetic SHR kidney.
Clark et al 2008 c-Jun N-terminal kinase mediates Ang II-speciﬁ  c astrocyte proliferation.
Donoghue et al 2000 This study identiﬁ  es ACE2 as the ﬁ  rst known human homologue of ACE, an enzyme that plays a central role in 
vascular, renal, and myocardial physiology. In contrast to ACE, however, ACE2 is highly tissue-speciﬁ  c: whereas 
ACE is expressed ubiquitously in the vasculature, human ACE2 is restricted to heart, kidney, and testis.
Ferrario et al 2004 Lisinopril augmented plasma levels and urinary excretion rates of Ang I and Ang-(1-7), while plasma Ang II was 
reduced with no effect on urinary Ang II. Losartan produced similar changes in plasma and urinary Ang-(1-7) 
but increased plasma Ang II without changing urinary Ang II excretion. This study revealed a role for ACE2 in 
Ang-(1-7) formation from Ang II in the kidney of normotensive rats as primarily reﬂ  ected by the increased ACE2 
activity measured in renal membranes from the kidney of rats given either lisinopril or losartan.
Fraga-Silva et al 2008 This study is the ﬁ  rst to show the presence of Mas protein and speciﬁ  c binding for Ang-(1-7) in rat and mouse plate-
lets. It also suggests that the Ang-(1-7) antithrombotic effect involves Mas-mediated NO release from platelets.
Furuhashi et al 2004 RAS blockade decreases adipocyte size in rats without change in epididymal %fat pads accompanied by improvement 
in insulin sensitivity.
Gallagher et al 2004 The results of this study suggest that Ang-(1-7) inhibits lung cancer cell growth through the activation of an 
angiotensin peptide receptor and may represent a novel chemotherapeutic and chemopreventive treatment for 
lung cancer.
Herath et al 2007 RAS activation in chronic liver injury was shown to be associated with upregulation of ACE2, Mas and hepatic 
conversion of angiotensin II to angiotensin-(1-7) leading to increased circulatting angiotensin-(1-7).
Jackman et al 2002 The two derivatives of Ang I, Ang 1-9, and Ang 1-7, liberated by enzymes in heart tissues, were shown to enhance 
the local effects of kinins by augmenting NO and arachidonic acid release.
Jankowski et al 2007 Ang A was shown to be a novel human strong vasoconstrictive angiotensin-derived peptide. Plasma Ang A 
concentration seems to be increased in end-stage renal failure. Because of its stronger agonism at the AT2 receptor, 
it is suggested that Ang A may modulate the harmful effects of Ang II.
Kohlstedt et al 2004 ACE was shown to be involved in outside-in signaling in endothelial cells and “ACE signaling” was suggested to 
be an important cellular mechanism contributing to the beneﬁ  cial effects of ACE inhibitors
Kostenis et al 2005 This study showed that Mas can hetero-oligomerize with the AT1 receptor and by so doing inhibit the actions of 
angiotensin II. This is a novel demonstration that a G-protein-coupled receptor acts as a physiological antagonist 
of a previously characterized receptor.
Lau et al 2004 The data coming from this study indicate the existence of an islet angiotensin-generating system of potential 
importance in the physiological regulation of glucose-induced insulin secretion, thus diabetes mellitus.
Lupi et al 2006 RAS molecules were shown in human islets and their expression was sensitive to glucose concentration. ACE 
inhibitors, and in particular zofenoprilat, protected human islets from glucotoxicity and the effects of ACE inhibition 
were associated with decreased oxidative stress.
Maia et al 2004 This study suggests that endogenous Ang-(1-7) and/ or an Ang-(1-7)-related peptide plays an important role in 
the BK potentiation by ACEI through a mechanism not dependent upon inhibition of ACE hydrolytic activity.
Nagata et al 2006 The identiﬁ  cation of proangiotensin-12 suggests a processing cascade of the RA system, different from the cleavage 
of angiotensinogen to Ang I by renin.
Nguyen et al 2002 This study highlights the role of the cell surface in angiotensin II generation and opens new perspectives on the 
tissue renin-angiotensin system and on renin effects independent of angiotensin II.
Paizis et al 2005 ACE2 expression is signiﬁ  cantly increased in liver injury in both humans and rat, and may modulate RAS 
activity in cirrhosis.
Pereira et al 2007 This study showed in a model of hepatic ﬁ  brosis the RAS activation. It also suggested that Ang-(1-7) played a 
protective role in hepatic ﬁ  brosis.
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In addition, the renal RAS is clearly activated in DM, 
with increased tissue Ang II (Giacchetti et al 2005) that 
leads to the development of diabetic nephropathy, a major 
cause of end-stage renal disease. Blockade of the RAS could 
thus reduce tissue Ang II levels, with beneﬁ  cial effects on 
cardiovascular and renal function.
The so-called metabolic syndrome, now regarded as a 
global epidemic, includes obesity, insulin resistance, dyslipid-
emia, and hypertension, often with hypertriglyceridemia and 
reduced high-density lipoprotein, as well as hyperuricemia and 
increased C-reactive protein (Meigs 2003). These features are 
often associated with endothelial cell dysfunction with impaired 
control of vascular tone, increased adhesiveness of leukocytes, 
and increased formation of growth factors and cytokines. These 
processes have been implicated in the development of diabetes, 
hypertension, heart failure, atherosclerosis, and renal failure. In 
this context, RAS components, mostly Ang II, have a potential 
role in endothelial cell dysfunction, insulin resistance, inﬂ  am-
mation, and proliferative effects (Watanabe et al 2005).
Interactions between RAS, 
endothelium, and insulin signaling 
pathways
The endothelium is a dynamic autocrine and paracrine 
organ that regulates vascular tonus and the interaction of 
the vascular wall with circulating substances and plasma 
cells (Cardillo and Panza 1998). It produces vasodilator and 
vasoconstrictor substances that are in balance under normal 
conditions. The health of the vascular net depends though 
on the normal operation of the endothelium. The endothelial 
dysfunction has been considered an imbalance in which the 
vasoconstrictor effects overcome the vasodilator ones in 
the vascular tonus (Jansson 2007; Pechánová et al 2007). 
This imbalance leads to a decrease of NO activity, which 
implies in a damage of the vascular protection (Pechánová 
et al 2007). The endothelium generally acts as a preventing 
barrier to the exocytose of macrophages and of low-density 
lipoproteins (LDL) to the subendothelium, and, thus protects 
against the atherosclerosis process (Romeo et al 2007).
The RAS can inﬂ  uence the vascular function by several 
ways, and studies have shown AT1 and AT2 receptors in the 
endothelium cells (Jacques et al 2003), besides evidence of 
Mas receptors, the Ang-(1-7) receptor (Sampaio et al 2007a, 
2007b). Ang II generally exhibits a vasoconstrictor effect on 
the endothelium while Ang-(1-7) is preferentially a vasodila-
tor peptide (Sampaio et al 2007b). Thus, the balance of these 
angiotensins’ effects is probably involved in the maintenance 
of endothelium integrity. It is well established that Ang II 
produces endothelial dysfunction through different pathways, 
such as increasing the oxidative stress (Agarwal 2003) and 
Table 1 Continued
Sampaio et al 2007a This study demonstrated that, in human endothelial cells, Ang-(1-7) negatively modulates Ang II/Ang II type 
1 receptor-activated c-Src and its downstream targets ERK1/2 and NAD(P)H oxidase. They also show that 
SHP-2-c-Src interaction is enhanced by Ang-(1-7).
Sampaio et al 2007b They demonstrated that Ang-(1-7), through Mas, stimulates eNOS activation and NO production via Akt-
dependent pathways.
Santos et al 2008 The results from this study showed that Mas deﬁ  ciency in FVB/N mice leads to dramatic changes in glucose 
and lipid metabolisms, inducing a metabolic syndrome-like state.
Sarzani et al 2008 Cell proliferation was progressively stimulated by increasing  Ang II concentrations and inhibited by atrial natriuretic 
pepetide in both visceral mature adipocytes and in vitro-differentiated preadipocytes. Co-incubation with increasing 
Ang II concentrations and valsartan indicated that Ang II effects were AT1-mediated.
Tallant et al 2005 The use of transfection of cultured myocytes with an antisense oligonucleotide to the mas receptor blocked in 
this model the ANG-(1-7)-mediated inhibition of serum-stimulated MAPK activation, whereas a sense oligonucle-
otide was ineffective. These results suggested that ANG-(1-7) reduced the growth of cardiomyocytes through 
activation of the mas receptor.
Tikellis et al 2003 This study showed by immunostaining that both ACE2 and ACE protein were localized predominantly to renal 
tubules. In the diabetic kidney, there was reduced ACE2 protein expression that was prevented by ACE inhibi-
tor therapy.
Vincent et al 2003 This study concludes that insulin speciﬁ  cally recruits ﬂ  ow to the microvasculture in skeletal muscle via a nitric oxide-
dependent pathway and that this may be important to insulin’s overall action to regulate glucose disposal.
Zisman et al 2003 This study showed that Ang-(1-7)-forming activity from both Ang I and Ang II was increased in failing human heart 
ventricles but it was mediated by at least two different angiotensinases. The ﬁ  rst, which demonstrated substrate 
preference for Ang I, was neutral endopeptidase-like. The second was ACE2, as demonstrated by Western blotting 
and inhibition of activity with C16.Vascular Health and Risk Management 2008:4(4) 795
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Table 2 Summary of recent clinical research on renin–angiotensin system
Author Results/Interpretations
Bojestig et al 2000 PRA and Ang II concentrations were signiﬁ  cantly lower in diabetic patients than in the controls. 
The levels of atrial natriuretic peptide, on the other hand, were higher in patients than in controls. 
PRA correlated negatively to the mean value of HbA(1c) during the previous ﬁ  ve years.
Brenner et al 2001 for the RENAAL Study Losartan reduced the incidence of a doubling of the serum creatinine concentration (risk reduction, 
25%; P = 0.006) and end-stage renal disease (risk reduction, 28%; P = 0.002) but had no effect on 
the rate of death. Losartan conferred signiﬁ  cant renal beneﬁ  ts in patients with type 2 diabetes and 
nephropathy.
Dahlof et al 2002 Losartan prevents more cardiovascular morbidity and death than atenolol for a similar reduction 
in blood pressure and is better tolerated. Losartan seems to confer beneﬁ  ts beyond reduction in 
blood pressure, and new-onset diabetes was less frequent with losartan.
Gross et al 2007 The survey of speciﬁ  c functional polymorphisms of the RAS, namely the angiotensin-I-converting 
enzyme (ACE) D/I, the angiotensinogen (AGT) T174M and M235T, and A1166C of the angiotensin-II 
receptor 1 (AGTR1), revealed that the incidence recurrent in-stent restenosis in a high-risk cohort 
was not associated with any of the polymorphisms examined in this study.
Gumprecht et al 2000 The results of this study suggest that ACE gene insertion/deletion and angiotensinogen M235T 
polymorphisms contribute to the increased risk for the development of chronic renal failure,
HOPE 2000 Ramipril was beneﬁ  cial for cardiovascular events and overt nephropathy in people with diabetes. 
The cardiovascular beneﬁ  t was shown to be greater than that attributable to the decrease in 
blood pressure.
Lieb et al 2006 This study provides evidence that genetic variants in the ACE2 gene may be associated with left 
ventricular mass, septal wall thickness, and left ventricular hypertrophy in hemizygous men.
Lewis et al 2001 The angiotensin-II-receptor blocker irbesartan was effective in protecting against the progres-
sion of nephropathy due to type 2 diabetes. This protection was independent of the reduction 
in blood pressure it causes.
Lindholm et al 2002 Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality 
as well as mortality from all causes in patients with hypertension, diabetes, and left ventricular 
hypertrophy. Losartan seems to have beneﬁ  ts beyond blood pressure reduction.
Matayoshi et al 2007 This study shows that the systemic RAS may modulate insulin sensitivity in essential hypertensive 
patients.
Merrill et al 2002 This study demonstrates, for the ﬁ  rst time, increased plasma Ang-(1-7) in normal pregnant subjects 
compared with nonpregnant subjects and decreased Ang-(1-7) in preeclamptic subjects compared 
with normal pregnant subjects.
Mukai et al 2002 The results of this study demonstrate that long-term inhibition of the renin-angiotensin system 
ameliorates endothelial dysfunction associated with aging through the inhibition of the synthesis 
of COX-2-derived vasoconstricting factors and superoxide anions.
Nogueira et al 2007 This study suggests that reduced levels of the vasodilator Ang-(1-7) could be implicated in the 
endothelial dysfunction seen in gestational diabetic women during and after pregnancy.
Parving et al 2001 This study showed that Irbesartan is renoprotective independently of its blood-pressure-lowering 
effect in patients with type 2 diabetes and microalbuminuria
Simões e Silva et al 2006b This study showed different circulating RAS proﬁ  les between hypertensive and in normotensive 
chronic renal failure subjects. Marked changes in plasma Ang-(1-7) were associated with the presence 
of hypertension and progression of kidney dysfunction.
Simões e Silva et al 2004 This study showed different RAS proﬁ  les in childhood hypertension and suggested a blood pres-
sure-independent change of Ang-(1-7) in essential hypertension.
Wijpkema et al 2006 In this study, the authors could establish a role for the AT1R 1166A/C polymorphism in 
restenosis after percutaneous coronary intervention. However, signiﬁ  cant gene – gene interaction 
was suggested for the ACE gene and the HO-1 promotor, meriting further investigation in 
restenosis.
Winkelmann et al 1999 The signiﬁ  cant relations observed in this study between the AGT M235T variant, its protein product, 
and the cardiovascular disease phenotypes provide evidence for a possible role of elevated circulating 
angiotensinogen in the pathogenesis of coronary artery disease.
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exerting proliferative (Clark et al 2008) and prothrombotic 
activities (Spillert et al 1994; Watanabe et al 2005). Ang II 
also stimulates the production of superoxide radicals, TGF-β, 
endothelin, and plasminogen activator inhibitor (PAI-1), 
which ultimately interferes in NO action (Rodrigues et al 
2007). Thus, there is enough evidence that Ang II accumula-
tion damages the endothelium and leads to atherosclerosis 
(Watanabe et al 2005; Cippolone et al 2006). However, 
other mediators are also responsible for endothelial function 
regulation (Savoia and Schiffrin 2007). In this regard, the 
vasoconstriction actions produced by Ang II and endothelin 
are probably opposed by the release of NO, prostaglandins, 
bradykinin as well as by Ang-(1-7). Furthermore, Ang-(1-7) 
promotes the release of NO and prostaglandins (Brosnihan 
et al 1996; Pörsti et al 1994) and potentiates bradykinin 
effects in different experimental models (Paula et al 1995; 
Brosnihan et al 1996; Maia et al 2004). In addition, Ang 
(1-7) also inhibits the growth of VSMC (Freeman et al 1996), 
platelet aggregation and thrombosis (Kucharewicz et al 2002; 
Fraga-Silva et al 2008), inﬂ  ammation, ﬁ  brosis (Pereira et al 
2007), and oxidative stress (Benter et al 2008), which in turn 
might lead to endothelial function restoration.
Indeed, Ang-(1-7) can antagonize Ang II effects not only 
by the stimulation of other vasodilators but also through AT1 
receptor inhibition. In this regard, Kostenis and colleagues 
(2005) reported that Mas receptor seems to act as a physi-
ological antagonist of AT1 receptor and by so counteracts 
many Ang II actions (Figure 1).
Alterations in the synthesis and degradation of endothe-
lial factors have recently been described as a contributor to 
the beginning or maintenance of a series of complications, 
including changes in vascular reactivity, blood ﬂ  ow, and tissue 
perfusion, which are all present in diabetes, renal diseases, 
heart failure, and hypertension (Kang et al 2002; Simões e 
Silva et al 2006c; Nakagawa et al 2007). Recently, studies 
have shown the presence of reduced levels of Ang-(1-7) in 
pregnancy complicated by pre-eclampsia (Merril et al 2002) 
and gestational diabetes (Nogueira et al 2007), corroborating 
to the hypothesis that changes in circulating levels of Ang-(1-
7) can be a marker of a new onset endothelial dysfunction.
Clinical and experimental evidence show that ACE 
inhibitors and AT1 receptor blockers clearly improve endo-
thelial dysfunction. Many mechanisms might take part in this 
effect and one of them is the increase of bradykinin levels with 
ACE inhibitors (Weir 2007). Considering that the treatment 
with RAS blockers (ACE inhibitors and AT1 receptor block-
ers) also increases Ang-(1-7) levels (Campbell 2003; Simões 
e Silva et al 2006b), our group and other investigators have 
speculated that the beneﬁ  cial action of RAS blockade could 
be, at least in part, due to Ang-(1-7) effects (Simões e Silva 
et al 2006a; Santos and Ferreira 2007; Chappell 2007).
Table 2 Continued
Yang et al 2007 The results of this study indicate that common genetic variants in the ACE2 gene might impact on 
myocardial infarction in females, and may possibly interact with alcohol consumption to affect the 
risk of coronary heart disease and myocardial infarction in Chinese males.
Yusuf et al 2001 This study demonstrated that ramipril is associated with lower rates of new diagnosis of diabetes 
in high-risk individuals.
Zhong et al 2006 This study concluded that the ACE2 A/G polymorphism is associated with hypertension in patients 
with metabolic syndrome.
Zisman et al 2003 This study showed that Ang-(1-7)-forming activity from both Ang I and Ang II was increased in 
failing human heart ventricles but it was mediated by at least two different angiotensinases. The 
ﬁ  rst, which demonstrated substrate preference for Ang I, was neutral endopeptidase-like. The 
second was ACE2, as demonstrated by Western blotting and inhibition of activity with C16.
Figure 2 Interactions between angiotensin II and insulin receptor in vascular smooth 
muscle cells.
Abbreviations: Ang II, angiotensin II; MAPK, mitogen-activated protein kinase; PAI 
1, plasminogen activator inhibitor-1; MCP 1, monocyte chemoattractant protein 
1; ICAM 1, intracellular cell adhesion molecule-1; PI3K, inositol 3-phosphatidil kinase; 
eNOS, endothelial nitric oxide synthase.
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In regard to diabetes, ACE inhibitors have also been 
associated to a decrease in the incidence of type 2 diabetes 
in hypertensive patients (Yusuf et al 2001; Vijayaraghavan 
and Deedwania 2005; Schmieder et al 2007), besides their 
wide spread utilization to prevent renal and cardiovascular 
diabetes complications (Weir 2007). Recent studies have 
shown an interaction between RAS and the insulin signaling 
pathways through AT1 receptors (Velloso et al 2006), and 
the utilization of AT1 receptor blockers have shown simi-
lar protective effects on renal and cardiovascular diabetes 
complications (Brenner et al 2001; Lindholm et al 2002). 
While Ang II may contribute to endothelial dysfunction and 
chronic diabetes complications, especially in the presence 
of insulin resistance (Hsueh and Quiñones 2003), treatment 
with ACE inhibitors or AT1 receptor blockers has shown to 
be protective in diabetes (Brenner et al 2001; Lindholm et al 
2002). However, these studies have not addressed the pos-
sible role of Ang-(1-7) in this unclear mechanism by which 
ACE inhibitors or AT1 receptor blockers prevent diabetes 
complications and novel diabetes onset.
Interactions between endothelial 
factors and insulin signaling
Several studies in humans and animals have shown that insu-
lin stimulated NO from the vascular endothelium represents 
an important physiologic role in the increase of the capillary 
recruitment and of the total blood ﬂ  ow to the skeletal muscle 
(Velloso et al 2006). The blunted endothelium NO-release 
has also been implicated in the reduction of capillary recruit-
ment and of total blood ﬂ  ow, leading to a state of low glucose 
availability that characterizes insulin resistance (Hsueh and 
Quiñones 2003; Vincent et al 2003).
Besides its NO-dependent effects in the vascular 
endothelium, insulin also interferes with hemodynamic 
homeostasis in insulin resistant states (Yki-Jarvinen 2003). 
In these conditions, insulin can act through MAP-K pathway, 
promoting cellular growth and other pro-inflammatory 
and pro-thrombotic actions (Velloso et al 2006). In obese 
individuals, it has been speculated a possible shift from PI3-K 
pathway, the molecular via for insulin signal transduction 
into action, to the MAP-K pathway, offering a molecular 
explanation by which hyperinsulinemia of these individuals 
might play a pro-atherogenic role (Hsueh and Quiñones 2003). 
There is also a possible interaction between insulin and local 
RAS at this level, since Ang II through AT1 receptors may 
stimulate the MAP-K pathway and, by doing so, promotes 
cellular proliferation, inﬂ  ammation and thrombosis (Velloso 
et al 2006), while the activation of AT2 receptors could inhibit 
this same via, meanwhile activating PI3-K (Bedecs et al 1997) 
(Figure 3). Although a possible antiproliferative action of 
Ang-(1-7) in this scenario is only speculative, experimental 
evidence with cardiomyocytes (Tallant et al 2005), pulmonary 
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tumor cells (Gallagher and Tallant 2004), and liver tissue 
(Pereira et al 2007; Herath et al 2007; Warner et al 2007) 
corroborates this possibility.
In addition, many studies have reported a connection 
between insulin resistance and RAS (Matayoshi et al 2007). 
It was shown that Ang II infusion induced insulin resistance 
(Richey et al 1999) and the blockade of the RAS improved 
insulin sensibility (Furuhashi et al 2004). In this regard, 
Santos and colleagues (2008) recently reported that, despite 
normal body weight, Mas-knockout mice in FVB/N back-
ground presented dyslipidemia, increased levels of insulin 
and leptin, and an approximately 50% increase in abdominal 
fat mass. Mas deletion also led to glucose intolerance and 
reduced insulin sensitivity as well as a decrease in insulin-
stimulated glucose uptake by adipocytes and decreased 
GLUT4 in adipose tissue. These results indicated that Mas 
deﬁ  ciency in FVB/N mice induces a metabolic syndrome-
like state. Further studies are obviously necessary to address 
the pathophysiological role of ACE2-Ang-(1-7)-Mas axis in 
human diabetes.
RAS, diabetes, and the endothelium
The cardiovascular morbidity and mortality related to dia-
betes, especially type 2 diabetes, are very high. Recently, 
cardiovascular risk has been reaching enormous proportions 
due to the obesity epidemic, metabolic syndrome, and type 2 
diabetes. Large clinical trials have been conducted to address 
the increase in renal and cardiovascular complications in the 
diabetic patient. The results of United Kingdom Prospective 
Diabetes Study (UKPDS), Reduction of Endpoints in Non-
Insulin-Dependent Diabetes Mellitus with the Angiotensin 
II Antagonist Losartan (RENAAL), Irbesartan Diabetic 
Nephropathy Trial (IDNT) Patients with Type 2 Diabetes and 
Microalbuminuria Study (IRMA2), and Heart Outcomes Pre-
vention Evaluation (HOPE and MICRO-HOPE) have shown 
that a well deﬁ  ned treatment of diabetic patients translated 
into renal and cardiovascular protection. Through these stud-
ies, it is now well established that prevention or reduction 
in proteinuria, blood pressure control, glycemic control, and 
particularly, the blockade of RAS are essential to prevent or 
delay the vascular diabetes complications. As already men-
tioned, RAS blockade has been shown not only a protective 
effect upon renal and cardiovascular complications of type 2 
diabetes (Weir 2007), but also reduce novel type 2 diabetes 
onset in hypertensive patients as shown by HOPE (Lindholm 
et al 2002) and LIFE studies (Dahlof et al 2002).
Studies of RAS in diabetes have shown conﬂ  ictive results 
regarding the activation of this system (Price et al 1999; 
Bojestig et al 2000). For example, in diabetes nephropathy, 
studies have shown a suppression of plasma renin activ-
ity (Bjork 1990), while tissue renin are generally elevated 
(Anderson et al 1993). Therefore, although the evaluation 
of the circulating RAS components may be of importance, 
it may not give full information of intra renal RAS compo-
nents.
Adipose tissue secretes a variety of hormones (known 
collectively as adipokines) that can modulate endothelial 
function. For example, TNF-α is a proinﬂ  ammatory cytokine 
secreted by adipose cells that may cause insulin resistance and 
endothelial dysfunction (Rydén and Arner 2007). In addition, 
components of RAS, including AGT, renin, ACE, Ang II, 
and the AT1 and AT2 receptors are present in adipose tissue 
(Sarzani et al 2008). Ang II, through AT1 receptor, is able to 
modulate insulin actions, and this may be due to inhibition of 
cross-talk between Ang II signaling and insulin signaling in 
metabolic and vascular tissues (Caglayan et al 2005). In this 
regard, the addition of Ang II to endothelial cells activates 
MAP-K pathways, leading to increased serine phosphory-
lation of IRS-1, impaired PI3-K activity, and endothelial 
dysfunction, which is abolished by AT1 receptor blockers 
(Nakashima et al 2006). In addition to effects on insulin 
signaling, the activation of AT1 receptors stimulates the 
production of ROS via NADPH oxidase, increases expres-
sion of ICAM-1, and ET-1 release from the endothelium 
(Caglayan et al 2005). Therefore, there are multiple direct 
and indirect mechanisms by which RAS contribute to insulin 
resistance and endothelial dysfunction through the modula-
tion of insulin signaling and other metabolic and vascular 
pathways (Caglayan et al 2005), supporting the therapeutic 
institution of RAS inhibition.
RAS blockade may be achieved through the inhibition of 
Ang II formation (with ACE or renin inhibitors), and through 
direct inhibition of AT1 receptors. In clinical scenario, ACE 
inhibitors and AT1 receptor blockers have been considered 
the most important ways of RAS blockade. The mechanism 
of action of ACE inhibitors results in accumulation of BK, 
whereas it does not occur with the AT1 receptor blockers. 
Other differences include the blockade of Ang II formation 
through ACE-independent pathways by AT1 receptor block-
ers (Li et al 2004), and a more prominent reduction of plasma 
blood ﬂ  ow by AT1 receptor blockers and renin inhibitors (Li 
et al 2004). However, these agents have exhibited similar 
beneﬁ  cial results in renal and cardiovascular diabetes com-
plications (Yusuf et al 2001; Lindholm et al 2002).
In the HOPE study, diabetes incidence was lower in the 
group treated with ramipril when compared with placebo Vascular Health and Risk Management 2008:4(4) 799
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(Yusuf et al 2001). In the LIFE (Losartan Intervention For 
Endpoint Reduction in Hypertension) study, the use of 
losartan was associated with a reduction in the occurrence 
of new diabetes onset as compared with atenolol (Lindholm 
et al 2002). Although the precise mechanisms involved on the 
reduction of new type 2 diabetes diagnosis by RAS inhibi-
tion are not well established, the increase in insulin mediated 
glucose uptake (Jamerson et al 1996), the improvement of 
endothelial function (Mukai et al 2002), a decrease in inﬂ  am-
matory response (Mervaala et al 1999), an increase in BK 
and Ang-(1-7) levels (Maia et al 2004), and an effect in local 
system in the pancreatic islets (Lau et al 2004) have been 
suggested as some of the putative factors (Cooper et al 2006). 
To date, many studies have placed RAS inhibition as of great 
importance to prevent cardiovascular diabetes complications 
(HOPE, LIFE, and RENAAL Studies).
Concerning its preventive actions in type 2 diabetes, RAS 
inhibition has also been shown to improve insulin sensitiv-
ity, allowing a better insulin action or a reduction in insulin 
dosages in some patients (De Mattia et al 1996). Several 
studies, utilizing clamps for insulin sensibility evaluation, 
have conﬁ  rmed these data in patients receiving ACE inhibi-
tors or AT1 blockers (Yki-Jarvinen 1995).
RAS inhibition is of importance in the prognosis of renal 
diabetes complications of both type 1 and type 2 diabetes. 
Renal Ang II increases the capillary glomerular pressure, 
which ultimately translates into hyperﬁ  ltration and protein-
uria (Navar et al 2000; Brewster and Perazella 2004). Delete-
rious Ang II effects have been demonstrated in experimental 
studies in which its infusion resulted in increase of intraglo-
merular pressure and protein excretion (Doria et al 1997). 
The resulting proteinuria associates to arterial hypertension 
and to the elevated risk of end stage renal disease, besides 
predicting cardiovascular complications of type 2 diabetes 
(Mogensen 1984; Deckert 1994). The beneﬁ  cial effects 
of ACE inhibitors or AT1 receptor blockers upon diabetes 
nephropathy have been understood, at least in part, as a 
result of the attenuation of Ang II effects on blood pressure 
and glomerular hemodynamics (Carey and Siragy 2003b; 
Kalantrina and Okusa 2006). Besides these hemodynamic 
actions, Ang II also stimulates TGFβ 1 and protein kinase 
C through AT1 receptors and thus increases extracellular 
matrix and vascular permeability (Kagami et al 1994; Wolf 
and Ziyadeh 1997; Carey and Siragy 2003b). These effects 
are quite similar to the results obtained with chronic hyper-
glycemia on the kidney, suggesting that the harmful renal 
hyperglycemic effects may be partially mediated by Ang II 
(Singh et al 1999). Of interest, hyperglycemia, the insulin 
resistance and the elevated free fatty acids may also stimulate 
renal Ang II generation, thus contributing to the pathogenesis 
of diabetes nephropathy (Carey and Siragy 2003b; Kalantrina 
and Okusa 2006). Furthermore, in the diabetic kidney, there 
was reduced ACE2 protein expression that was prevented 
by ACE inhibitor therapy (Tikellis et al 2003).
Many studies have also proven the role of ACE2 as a 
protective enzyme for cardiovascular diseases (see Table 
2). As the ACE2 gene is on the X chromosome, the studies 
correlating the ACE2 gene polymorphisms with cardiovas-
cular and metabolic diseases have to take the gender into 
consideration meanwhile performing data analyses (Lieb et al 
2006; Zhong et al 2006; Yang et al 2007). Although there is a 
lack of studies in this ﬁ  eld, particularly in diabetes, a Chinese 
study has shown that patients with the metabolic syndrome 
exhibit an association of ACE2 gene A/G polymorphism and 
elevated blood pressure (Zhong et al 2006). Further studies 
should investigate the importance of these polymorphisms in 
diabetes, and also verify if the known polymorphisms in the 
RAS genes that have been studied in restenosis after percu-
taneous coronary intervention (Gross et al 2007; Wijpkema 
et al 2006) would also play a prominent role in diabetes and 
coronary disease.
Therefore, the identiﬁ  cation of ACE2 in the kidney and 
cardiovascular system, its modulation in diabetes, and the 
recent description that this enzyme plays a biological role 
in the generation and degradation of various angiotensin 
peptides provide a rationale to further explore the role of 
ACE2-Ang-(1-7)-Mas axis in diabetic complications.
Concluding remarks
In conclusion, this review shows the physiology of the RAS, 
including the importance of novel mediators, receptors, and 
enzymatic pathways. It also shows how the current view of this 
system might impact diabetes and its complications, highlight-
ing the importance of RAS inhibition in this disease treatment. 
Furthermore, we also provide recent evidence for putative role 
of ACE2-Ang-(1-7)-Mas axis in diabetes pathogenesis.
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